Insight

Oct 16, 2024, 15:08

The utility of ctDNA clearance for personalizing consolidation immunotherapy after CRT for stage III NSCLC

Drew Moghanaki shared a post on X:

“A new publication from Max Diehn‘s group re-demonstrates the utility of ctDNA clearance for personalizing consolidation immunotherapy after CRT for stage III NSCLC.

Analysis of Circulating Tumor DNA Predicts Outcomes of Short-Course Consolidation Immunotherapy in Unresectable Stage III NSCLC

Authors: Soyeong Jun, Nikhil A. Shukla, Greg Durm, Angela B. Hui, Sha Cao, Apar Kishor Ganti, Salma K. Jabbour, Christian Kunder, Ash A. Alizadeh, Nasser H. Hanna, Maximilian Diehn.“

Dr. Drew Moghanaki, a Professor and Chief of Thoracic Oncology at the Department of Radiation Oncology, UCLA. He holds the Stanley Iezman and Nancy Stark Endowed Chair in Thoracic Radiation Oncology Research at the same university. He specializes in treating lung cancer and other thoracic malignancies, focusing on advanced radiation therapy techniques like stereotactic body radiation therapy (SBRT), magnetic resonance-guided radiation therapy (MRgRT), and intensity-modulated radiation therapy (IMRT).

Angela B. Hui Apar Kishor Ganti Ash A. Alizadeh cancer Christian Kunder CRT ctDNA Drew Moghanaki Greg Durm Maximilian Diehn Nasser H. Hanna Nikhil A. Shukla OncoDaily Oncology Salma K. Jabbour Sha Cao Soyeong Jun stage III NSCLC

New Paper Alert: Systemic management of advanced HCC: an increasingly complex game

AC-satoreotide got FDA Orphan Drug Designation status for SCLC and MCC

Oncologist Near Me – Nazik Hammad: A Leader in Cancer Care, Medical Education, and Health Equity

Garo Armen - A Bold Call to Action: Embracing Real-Time Innovation in Pediatric Cancer

Black History Month 2025: Honoring Contributions to Oncology